Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Robin Kate KelleyBruno SangroWilliam HarrisMasafumi IkedaTakuji OkusakaYoon-Koo KangShu-Kui QinDavid Wai-Meng TaiHo Yeong LimThomas YauWei Peng YongAnn-Lii ChengAntonio GasbarriniSilvia DamianJordi BruixMitesh J BoradJohanna BendellTae-You KimNathan StandiferPhilip HeMallory MakowskyAlejandra NegroMasatoshi KudoGhassan K Abou-AlfaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
All regimens were found to be tolerable and clinically active; however, the T300 + D regimen demonstrated the most encouraging benefit-risk profile. The unique pharmacodynamic activity and association with ORR of the T300 + D regimen further support its continued evaluation in HCC.